The Safety and Efficacy of Subcutaneous Enoxaparin Versus Intravenous Unfractionated Heparin and Tirofiban Versus Placebo in the Treatment of Acute ST-Segment Elevation Myocardial Infarction Patients Ineligible for Reperfusion (TETAMI): A Randomized Trial

Journal of the American College of Cardiology

Volumn 42, Issue 8, 2003, Pages 1348-1356

  Cohen, Marc ^a   Gensini, Gian Franco ^b   Maritz, Frans ^c   Gurfinkel, Enrique P ^d   Huber, Kurt ^e   Timerman, Ari ^f   Krzeminska Pakula, Maria ^g   Danchin, Nicolas ^h   White, Harvey D ⁱ   Santopinto, Jose ^j   Bigonzi, Frederique ^k   Hecquet, Carole ^k   Vittori, Luc ^k  

^a NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Karl Bremer Hospital   (South Africa)

^d HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^g MEDICAL UNIVERSITY OF LODZ   (Poland)

^h HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁱ GREEN LANE HOSPITAL   (New Zealand)

^j Leonidas Lucero Municipal Hospital   (Argentina)

^k SANOFI   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; HEPARIN; PLACEBO; TIROFIBAN;

ANGINA PECTORIS; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HEART MUSCLE REPERFUSION; HEART REINFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION;

EID: 10744232388     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)01040-4     Document Type: Article

References (36)

1. The American Heart Association. Heart and Stroke Facts: Statistical Supplement. Dallas, TX; The American Heart Association, 2003.
2. Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2003;24:28-66.
3. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1999;3:890-911.
4. Rogers WJ, Canto JG, Lambrew CT, et al., for the Investigators in the National Registry of Myocardial Infarction 1, 2 and 3. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the U.S. from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol 2000;36:2056-68.
5. Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, Lopez-Sendon J. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 2002;359:373-7.
6. Barron HV, Bowlby LJ, Breen T, et al. Use of reperfusion therapy for acute myocardial infarction in the United States: data from the National Registry of myocardial infarction 2. Circulation 1998;97: 1150-6.
7. LATE Study Group. Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993;342:759-66.
8. EMERAS (Estudio Multicentrico Estreptoquinasa Republicas de America del Sur) Collaborative Group. Randomized trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet 1993;342:767-72.
9. Horie H, Takahashi M, Minai K, et al. Long-term beneficial effect of late reperfusion for acute anterior myocardial infarction with percutaneous transluminal coronary angioplasty. Circulation 1998;98:2377-82.
10. Yousef ZR, Redwood SR, Bucknall CA, Sulke AN, Marber MS. Late intervention after anterior myocardial infarction: effects on left ventricular size, function, quality of life, and exercise tolerance: results of The Open Artery Trial (TOAT study). J Am Coll Cardiol 2002;40: 869-76.
11. Ottesen MM, Køber L, Jørgensen S, Torp-Pedersen C, on behalf of the TRACE Study Group. Consequences of overutilization and underutilization of thrombolytic therapy in clinical practice. J Am Coll Cardiol 2001;37:1581-7.
12. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial. Circulation 1999;100:1593-601.
13. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease: Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events Study Group. N Engl J Med 1997;337:447-52.
14. The ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab or unfractionated heparin: the ASSENT-3 randomized trial in acute myocardial infarction. Lancet 2001;358:605-13.
15. Ross AM, Molhoek P, Lundergan C, et al. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 2001;104:648-52.
16. Antman EM, Louwerenburg HW, Baars HF, et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis In Myocardial Infarction (TIMI) 23 trial. Circulation 2002;105:1642-9.
17. The Platelet Receptor inhibition in Ischemic Syndrome Management in Patients Limited by Unstable signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
18. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
19. PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina: Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998;338:1498-505.
20. Cohen M, Theroux P, Weber S, et al. Combination therapy in tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol 1999;71:273-81.
21. Cohen M, Theroux P, Borzak S, et al. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study: the Antithrombotic Combination Using Tirofiban and Enoxaparin. Am Heart J 2002;144: 470-7.
22. Cohen M, Maritz F, Gensini GF, et al. The TETAMI trial: the safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and of tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolyzed: methods and design. J Thromb Thrombolysis 2000;10:241-6.
23. Cohen M, Antman EM, Gurfinkel E, et al. Impact of enoxaparin low molecular weight heparin in patients with Q-wave myocardial infarction: a subgroup meta-analysis from the TIMI 11B and ESSENCE trials. Am J Cardiol 2000;86:553-6.
24. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty: randomized efficacy study of tirofiban for outcomes and restenosis. Circulation 1997;96:1445-53.
25. Pilote L, Califf RM, Sapp S, et al. Regional variation across the United States in the management of acute myocardial infarction. N Engl J Med 1995;333:565-72.
26. Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM. Sex-based differences in early mortality after myocardial infarction. N Engl J Med 1999;341:217-25.
27. MacIntyre K, Stewart S, Capewell S, et al. Gender and survival: a population-based study of 201,114 men and women following a first acute myocardial infarction. J Am Coll Cardiol 2001;38:729-35.
28. Mehta RH, Rathore SS, Radford MJ, Wang Y, Wang Y, Krumholz M. Acute myocardial infarction in the elderly: differences by age. J Am Coll Cardiol 2001;38:736-41.
29. Wu AH, Parsons L, Every NR, Bates ER. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction. J Am Coll Cardiol 2002;40:1389-94.
30. Zahn R, Schiele R, Schneider S, et al. Primary angioplasty versus no reperfusion therapy in patients with acute myocardial infarction and a pre-hospital delay of >12-24 hours: results from the pooled data of the maximal individual therapy in acute myocardial infarction (MITRA) registry and the Myocardial Infarction Registry (MIR). J Invasive Cardiol 2001;13:367-72.
31. Elad Y, French WJ, Shavelle DM, Parsons LS, Sada MJ, Every NR. Primary angioplasty and selection bias in patients presenting late (>12h) after onset of chest pain and ST elevation myocardial infarction. J Am Coll Cardiol 2002;39:826-33.
32. Srinivas VS, Vakili BA, Brown DL. Comparison of in-hospital outcomes following early or delayed angioplasty for acute myocardial infarction. J Invasive Cardiol 2002;14:746-50.
33. Bahit MC, Topol EJ, Califf RM, et al. Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. J Am Coll Cardiol 2001;37:1001-7.
34. Hudson MP, Granger CB, Topol EJ, et al. Early reinfarction after fibrinolysis: experience from the Global Utilization of Streptokinase and Tissue plasminogen activator (alteplase) for Occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. Circulation 2001;104:1229-35.
35. Furman MI, Dauerman HL, Goldberg RJ, et al. Twenty-two year (1975 to 1997) trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non-Q-wave myocardial infarction: a multi-hospital, community-wide perspective. J Am Coll Cardiol 2001;37:1571-80.
36. Herrmann HC, Swierkosz TA, Kapoor S, et al. Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol 2002;89: 1293-7.